## LIST OF TABLES

Table No.	Table description	Page No.
4.1	Effects of ambroxol on 6-OHDA-induced changes in motor functions as assessed by apomorphine-induced rotations, cataleptic behavior, grip strength score and rotarod retention time in rats.	44
4.2	Effects of ambroxol on 6-OHDA-induced alterations in motor functions as assessed by number of central squares crossed, ambulation, rearing and grooming in open field test in rats.	45
5.1	Effects of rebamipide on 6-OHDA-induced alterations in motor functions as assessed by apomorphine-induced rotations, cataleptic behavior, grip strength score and rotarod retention time in rats.	78
5.2	Effects of rebamipide on 6-OHDA-induced alterations in motor functions as assessed by number of central squares crossed, ambulation, rearing and grooming in open field test in rats.	79
6.1	Effects of rebamipide and Nrf2i on 6-OHDA-induced alterations in motor functions as assessed by apomorphine-induced rotations, cataleptic behavior, grip strength score and rotarod retention time in rats.	112
6.2	Effects of rebamipide and Nrf2i on 6-OHDA-induced alterations in motor functions as assessed by number of central squares crossed, ambulation, rearing and grooming in open field test in rats.	113

7.1	Ambroxol-induced recovery of motor functions as assessed by apomorphine-induced rotations, cataleptic behavior, grip strength score and rotarod retention time against 6-OHDA-induced motor deficits in rats.	149
7.2	Ambroxol-induced recovery of motor functions as assessed by the number of central squares crossed, ambulation, rearing and grooming in open field test against 6-OHDA-induced motor deficits in rats.	150
8.1	Rebamipide (R-80)-induced recovery of behavior symptoms as evaluated by apomorphine-induced rotations, cataleptic behavior, grip strength score and rotarod retention time against 6-OHDA-induced motor deficits in rats.	177
8.2	Rebamipide-induced recovery of behavioral symptoms as evaluated by the number of central squares crossed, ambulation, rearing and grooming in open field test against 6-OHDA-induced motor deficits in rats.	178
9.1	Formulation of Transdermal Patches	198
9.2	Absorbance values of rebamipide solution at different wavelengths, obtained from absorption spectra.	210
9.3	Physicochemical parameters (thickness, folding endurance, surface pH and drug content) of the formulated patches containing rebamipide.	212
9.4	Physicochemical parameters (weight, swelling and moisture loss) of the formulated patches containing rebamipide.	214
9.5	Visual observation for skin irritation test on rat skin.	220
9.6	Effects of rebamipide (oral and transdermal) on 6-OHDA-induced alterations in motor functions as assessed by	222

apomorphine-induced rotations, cataleptic behavior, grip strength score and rotarod retention time in rats.

**9.7** Plasma and CSF concentration of rebamipide.

227